MET-233I
A Study of MET233 in Individuals With Obesity or Overweight
Pfizer · Phase 1 · Completed · Enrollment 144
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| (Part A) MET233 | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part A) Placebo | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part B) MET233 | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part B) Placebo | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part C) MET233 | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part C) Placebo | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part D) MET233 | Obesity or overweight | n/r | 12 | n/r | n/r |
| (Part D) Placebo | Obesity or overweight | n/r | 12 | n/r | n/r |